{"Symbol": "ITCI", "AssetType": "Common Stock", "Name": "Intra-Cellular Therapies, Inc", "Description": "Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the central nervous system (CNS) in the United States. The company is developing its lead drug candidate, CAPLYTA for the treatment of schizophrenia, bipolar disorder, behavioral disturbances associated with dementia, autism, and other CNS diseases. It is also developing ITI-002 that inhibits the enzyme phosphodiesterase type 1; ITI-214 for Parkinson's disease; and ITI-333, for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. is headquartered in New York, New York.", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "Healthcare", "Industry": "Biotechnology", "Address": "430 East 29th Street, New York, NY, United States, 10016", "FullTimeEmployees": "330", "FiscalYearEnd": "December", "LatestQuarter": "2020-06-30", "MarketCapitalization": "1225643904", "EBITDA": "-161484432", "PERatio": "None", "PEGRatio": "0", "BookValue": "5.683", "DividendPerShare": "None", "DividendYield": "0", "EPS": "-2.814", "RevenuePerShareTTM": "0.05", "ProfitMargin": "0", "OperatingMarginTTM": "-62.9695", "ReturnOnAssetsTTM": "-0.3198", "ReturnOnEquityTTM": "-0.5864", "RevenueTTM": "3050728", "GrossProfitTTM": "-89064225", "DilutedEPSTTM": "-3.084", "QuarterlyEarningsGrowthYOY": "0", "QuarterlyRevenueGrowthYOY": "0", "AnalystTargetPrice": "45.25", "TrailingPE": "0", "ForwardPE": "0", "PriceToSalesRatioTTM": "359.9699", "PriceToBookRatio": "3.2187", "EVToRevenue": "275.0094", "EVToEBITDA": "0", "Beta": "1.7907", "52WeekHigh": "43.56", "52WeekLow": "7.08", "50DayMovingAverage": "20.5433", "200DayMovingAverage": "20.1962", "SharesOutstanding": "67306096", "SharesFloat": "59195041", "SharesShort": "5311551", "SharesShortPriorMonth": "4930215", "ShortRatio": "7.6", "ShortPercentOutstanding": "0.07", "ShortPercentFloat": "0.0844", "PercentInsiders": "6.066", "PercentInstitutions": "69.587", "ForwardAnnualDividendRate": "0", "ForwardAnnualDividendYield": "0", "PayoutRatio": "0", "DividendDate": "None", "ExDividendDate": "None", "LastSplitFactor": "None", "LastSplitDate": "None"}